Forbes questions Wegovy's path into Medicare Part D coverage
The commentary asks whether Novo Nordisk's semaglutide will be treated as a Part D drug, a bridge product, or neither.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 16 11:49 ETSource: Forbes
The wire
- 01A Forbes column examines how Wegovy might be classified under Medicare drug coverage rules.
- 02Medicare treatment of obesity drugs would reshape demand for semaglutide and rival GLP-1s.
- 03No policy decision has been announced; the piece is analysis.
From the source
Read at news.google.comWill Wegovy Be A Part D, A Medicare GLP-1 Bridge Drug Or Neither?